Volume Spike Investor

Vical (VICL) is up 16% to $4.86 on news about the the presentation of encouraging results from animal studies of a peptide-based cancer vaccine formulated with the company’s Vaxfectin(R) adjuvant. Sean M. Sullivan, Ph.D., Vical’s Executive Director of Pharmaceutical Sciences, is presenting data at the IIRUSA Vaccines Development Forum (Boston – September 23-25) demonstrating the adjuvant’s ability to enhance immune responses of cancer antigen-based vaccines in addition to a broad variety of DNA- and protein-based vaccines against infectious diseases.

Douglas A. McIntyre